390 related articles for article (PubMed ID: 28720427)
1. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.
Fessler MB
Pharmacol Ther; 2018 Jan; 181():1-12. PubMed ID: 28720427
[TBL] [Abstract][Full Text] [Related]
2. Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.
Ishibashi M; Filomenko R; Rébé C; Chevriaux A; Varin A; Derangère V; Bessède G; Gambert P; Lagrost L; Masson D
Biochem Pharmacol; 2013 Jul; 86(1):122-9. PubMed ID: 23313547
[TBL] [Abstract][Full Text] [Related]
3. Activation of the Liver X Receptor Pathway Inhibits HBV Replication in Primary Human Hepatocytes.
Zeng J; Wu D; Hu H; Young JAT; Yan Z; Gao L
Hepatology; 2020 Dec; 72(6):1935-1948. PubMed ID: 32145089
[TBL] [Abstract][Full Text] [Related]
4. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
[TBL] [Abstract][Full Text] [Related]
5. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms.
Morello F; Saglio E; Noghero A; Schiavone D; Williams TA; Verhovez A; Bussolino F; Veglio F; Mulatero P
Atherosclerosis; 2009 Nov; 207(1):38-44. PubMed ID: 19426978
[TBL] [Abstract][Full Text] [Related]
6. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice.
Zhang Y; Breevoort SR; Angdisen J; Fu M; Schmidt DR; Holmstrom SR; Kliewer SA; Mangelsdorf DJ; Schulman IG
J Clin Invest; 2012 May; 122(5):1688-99. PubMed ID: 22484817
[TBL] [Abstract][Full Text] [Related]
7. Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
Bełtowski J
Cardiovasc Ther; 2008; 26(4):297-316. PubMed ID: 19035881
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.
Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA
Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796
[TBL] [Abstract][Full Text] [Related]
9. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.
Guo Y; Yuan W; Yu B; Kuai R; Hu W; Morin EE; Garcia-Barrio MT; Zhang J; Moon JJ; Schwendeman A; Eugene Chen Y
EBioMedicine; 2018 Feb; 28():225-233. PubMed ID: 29361501
[TBL] [Abstract][Full Text] [Related]
10. Liver X receptor: a potential target in the treatment of atherosclerosis.
Savla SR; Prabhavalkar KS; Bhatt LK
Expert Opin Ther Targets; 2022 Jul; 26(7):645-658. PubMed ID: 36003057
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of notch enhances the anti-atherosclerotic effects of LXR agonists while reducing fatty liver development in ApoE-deficient mice.
Hao Y; Wang X; Zhang F; Wang M; Wang Y; Wang H; Du Y; Wang T; Fu F; Gao Z; Zhang L
Toxicol Appl Pharmacol; 2020 Nov; 406():115211. PubMed ID: 32853627
[TBL] [Abstract][Full Text] [Related]
12. The medicinal chemistry of liver X receptor (LXR) modulators.
Tice CM; Noto PB; Fan KY; Zhuang L; Lala DS; Singh SB
J Med Chem; 2014 Sep; 57(17):7182-205. PubMed ID: 24832115
[TBL] [Abstract][Full Text] [Related]
13. 1α-Hydroxy derivatives of 7-dehydrocholesterol are selective liver X receptor modulators.
Endo-Umeda K; Aoyama A; Shimizu M; Ishikawa M; Hashimoto Y; Yamada S; Makishima M
J Steroid Biochem Mol Biol; 2017 Sep; 172():136-148. PubMed ID: 28736297
[TBL] [Abstract][Full Text] [Related]
14. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
15. Liver X receptor activation inhibits SGLT2-mediated glucose transport in human renal proximal tubular cells.
Chonlaket P; Wongwan T; Soodvilai S
Exp Physiol; 2018 Feb; 103(2):250-260. PubMed ID: 29127736
[TBL] [Abstract][Full Text] [Related]
16. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr
Yu M; Amengual J; Menon A; Kamaly N; Zhou F; Xu X; Saw PE; Lee SJ; Si K; Ortega CA; Choi WI; Lee IH; Bdour Y; Shi J; Mahmoudi M; Jon S; Fisher EA; Farokhzad OC
Adv Healthc Mater; 2017 Oct; 6(20):. PubMed ID: 28730752
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling.
Ogihara T; Chuang JC; Vestermark GL; Garmey JC; Ketchum RJ; Huang X; Brayman KL; Thorner MO; Repa JJ; Mirmira RG; Evans-Molina C
J Biol Chem; 2010 Feb; 285(8):5392-404. PubMed ID: 20007976
[TBL] [Abstract][Full Text] [Related]
18. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator.
Miao B; Zondlo S; Gibbs S; Cromley D; Hosagrahara VP; Kirchgessner TG; Billheimer J; Mukherjee R
J Lipid Res; 2004 Aug; 45(8):1410-7. PubMed ID: 15145986
[TBL] [Abstract][Full Text] [Related]
19. Intestine-specific regulation of PPARalpha gene transcription by liver X receptors.
Colin S; Bourguignon E; Boullay AB; Tousaint JJ; Huet S; Caira F; Staels B; Lestavel S; Lobaccaro JM; Delerive P
Endocrinology; 2008 Oct; 149(10):5128-35. PubMed ID: 18566121
[TBL] [Abstract][Full Text] [Related]
20. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries.
Blaschke F; Leppanen O; Takata Y; Caglayan E; Liu J; Fishbein MC; Kappert K; Nakayama KI; Collins AR; Fleck E; Hsueh WA; Law RE; Bruemmer D
Circ Res; 2004 Dec; 95(12):e110-23. PubMed ID: 15539633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
